AVROBIO, Inc. (AVRO)
Chart Events
Performance Outlook
| Previous Close | 14.00 |
| Open | 14.13 |
| Bid | 13.87 x 1200 |
| Ask | 14.60 x 900 |
| Day's Range | 13.81 - 14.23 |
| 52 Week Range | 9.76 - 29.32 |
| Volume | 322,633 |
| Avg. Volume | 245,495 |
| Market Cap | 581.556M |
| Beta (5Y Monthly) | 1.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.31 |
| Earnings Date | Nov 05, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.86 |
- Business Wire
AVROBIO Announces Closing of Underwritten Public Offering
AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock. The aggregate gross proceeds to the company from the offering, before deducting underwriting discounts and commission and estimated offering expenses, totaled $75 million. As previously announced, the company has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.
- Business Wire
AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock
AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. Gross proceeds from the underwritten public offering will total approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses payable by the company. In addition, the company has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are to be sold by the company. The offering is expected to close on or about Nov. 24, 2020, subject to customary closing conditions.
- Business Wire
AVROBIO Announces Proposed Public Offering of Common Stock
AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its common stock in an underwritten public offering.
